Loading...
NPI 1861913576 · Rockville, MD · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Cirrus Dx, Inc. is a clinical medical laboratory provider located in Rockville, Maryland. This profile covers 23 Medicare and 25 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Cirrus Dx, Inc. |
| Address | 77 Upper Rock Cir Ste 400 |
| City | Rockville |
| State | MD |
| ZIP | 20850 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 3, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.8M |
| Medicaid | $906.9K |
CIRRUS DX, INC. operates as a high-volume clinical diagnostic laboratory focused on nucleic acid and amplified probe testing, as evidenced by its Medicare top-line codes which are dominated by molecular infectious-agent assays such as 87798, 87900, and 87799. The code descriptions show a service mix oriented to amplified nucleic acid probe techniques, quantification assays, and antiviral susceptibility testing — consistent with a specialized molecular diagnostics lab rather than a general anatomic pathology or point-of-care provider.
Medicare revenue is concentrated: the precomputed top 3 Medicare codes account for 60.8% of this provider’s total Medicare revenue, indicating heavy dependence on a small set of molecular test types. On Medicare the single largest code is 87798 (38.5% of Medicare revenue) followed by 87900 (11.3%) and 87799 (11.0%), so any changes in reimbursement or demand for these specific assays would materially affect overall Medicare receipts.
On Medicaid the provider also shows concentration: the top 3 Medicaid codes account for 59.9% of total Medicaid revenue, with U0004 (31.6%) and 87798 (20.1%) together representing the majority of Medicaid receipts. This pattern suggests the lab’s Medicaid volume is similarly driven by a narrow menu of infectious-disease molecular tests, particularly SARS-CoV-2 high-throughput testing and unspecified amplified-probe assays.
Payer mix is skewed toward Medicare by scale: lifetime Medicare revenue is $7.8M versus lifetime Medicaid revenue of $906.9K, indicating Medicare is the dominant source of government payer income for this entity. While both payers show similar code concentration, the Medicare book of business is roughly an order of magnitude larger in absolute dollars using the provided rounded figures.
CIRRUS DX is a major competitive outlier on several Medicare codes nationally: it ranks #1 of 94 for 87900 (labeled an "extreme outlier"), #1 of 246 for 87799 ("extreme outlier"), and holds top or near-top national percentiles for multiple other molecular codes (several 98–100th percentile and many 99th). This indicates the provider is a dominant national-volume performer for specific specialized molecular assays, not merely a local or average-volume lab for those tests.
In the Maryland Medicaid market the provider is often among the highest-volume in-state performers for several codes: it ranks #5 of 32 for U0004 (87th percentile), #1 of 11 for 87500 (100th percentile), and #1 of 5 for 87900 (100th percentile in-state). These ranks indicate a strong regional position for COVID and certain probe-based infectious-agent tests within Maryland's Medicaid network.
Several individual codes are flagged as extreme outliers or notably above typical national volume on Medicare (for example 87900 and 87799 as "extreme outlier", and multiple codes at 98–99th percentiles), which signals unusually high specialization and throughput on those assays relative to national peers. Analysts should treat these listed labels as indicators of exceptional relative volume rather than conclusions about clinical appropriateness.
The provider has been enumerated for approximately 9 years (NPI registered ~2017-07-03), giving it an established operational history in the Medicare/Medicaid billing data. This tenure, combined with repeated top-percentile ranks across molecular test codes, suggests an intentional, sustained business model centered on high-throughput molecular infectious-disease testing rather than a recently pivoted or transient operation.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
23 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 87,620 | $30 | $3M |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 6,830 | $130 | $874.8K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 20,190 | $40 | $847.9K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 20,130 | $30 | $684.5K |
| 87482 | The lab analyst performs a test to quantify infection with Candida species using nucleic acid probe technique. | 6,750 | $60 | $371K |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 6,820 | $40 | $279.5K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 6,870 | $30 | $233.5K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 6,820 | $30 | $231.8K |
| 87186 | The lab analyst performs the technical steps to evaluate a culture isolate’s susceptibility, or sensitivity, to multiple antimicrobial agents, commonly called antibiotics, by observing growth of the… | 28,940 | $10 | $231.5K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 6,760 | $30 | $229.9K |
Showing 1–10 of 23
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 23 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
23 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87900 | 1 | 10 | 110 | $130 | $297.8K |
| 87482 | 1 | 10 | 3,810 | $50 | $207.8K |
| 87798 | 2 | 60 | 1,430 | $30 | $170.3K |
| 87563 | 1 | 10 | 510 | $30 | $58.5K |
| 87481 | 2 | 60 | 160 | $30 | $48.7K |
| 87799 | 1 | 30 | 140 | $40 | $42.1K |
| 87186 | 1 | 20 | 670 | $10 | $39.6K |
| 87637 | 9 | 20 | 130 | $140 | $39.5K |
| U0004 | 1 | 10 | 240 | $70 | $39.2K |
| 87801 | 10 | 20 | 140 | $70 | $34.7K |
Showing 1–10 of 23
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
25 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 12,990 | $20 | $285.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,540 | $40 | $181.4K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 2,570 | $30 | $74.4K |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 3,200 | $20 | $73.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,070 | $10 | $40.6K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 4,890 | $10 | $34.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 4,130 | $10 | $33K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 4,100 | $10 | $32.8K |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 3,370 | $10 | $30.3K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 3,770 | $10 | $30.2K |
Showing 1–10 of 25
How this provider's Medicaid billing volume and revenue compare to other Maryland providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Maryland median
25 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 29 | 50 | 660 | $30 | $289.2K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 29 | 50 | 640 | $30 | $284.4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 5 | 30 | 710 | $40 | $267.8K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 4 | 10 | 1,650 | $30 | $225.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 20 | 30 | 1,010 | $20 | $152.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6 | 40 | 320 | $50 | $146.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 8 | 30 | 120 | $50 | $132.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 6 | 20 | 1,690 | $30 | $120.4K |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 1 | 10 | 1,500 | $50 | $78.2K |
| 87490 | The lab analyst performs a test for Chlamydia trachomatis using direct nucleic acid probe technique. Chlamydia trachomatis causes a common sexually transmitted disease and certain eye infections. | 2 | 10 | 540 | $130 | $73K |
Showing 1–10 of 25
Other providers in the same ZIP code as Cirrus Dx, Inc., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.